Cancer progression after targeted therapy creates a different problem from the one faced at diagnosis. The original molecular profile may still matter, but it may no longer tell the whole story.
Tumors can evolve under treatment pressure. The original target may change; alternative pathways may become more relevant, or resistant tumor populations may emerge. That is why molecular testing in cancer can become clinically relevant again after progression.
But progression alone is not necessarily a reason to retest. The more useful question is: could a new molecular finding change what happens next?
To understand how oncologists approach this decision, MDForLives surveyed oncology specialists across six countries. The findings suggest that repeat testing is used selectively, with its value shaped by actionability, treatment availability, and clinical context. The detailed findings are available in the MDForLives Targeted Therapy Resistance Insight Report.
Cancer progression can make an earlier molecular profile incomplete
A molecular profile reflects tumor biology at a particular point in the disease course. After targeted therapy, biology may evolve.
Understanding how targeted therapy for cancer works helps explain why changes in tumor biology can affect treatment response over time.
So, when cancer progression occurs, the first question is not simply whether another molecular test is available. It is whether there is reason to believe that identifying a new resistance mechanism could alter management.
An earlier profile may still provide important context, but it may not capture changes that emerged under treatment pressure.
For clinicians, the useful starting question becomes: “Would understanding what changed influence the next treatment decision?”
That keeps repeat testing connected to a specific clinical problem rather than making it an automatic response to every progression event.
Repeat molecular testing add more value in decision making
The MDForLives findings reflect this selective approach.
Among surveyed oncologists, 42.0% said they repeat molecular or biomarker testing selectively according to cancer type and treatment history.
The practical implication is to define the decision before ordering the test.
Cancer type, prior to targeted therapy, suspected resistance biology, available tissue, assay performance, treatment options, and disease-specific guidance can all influence whether another test is likely to add value.
If a new finding could change sequencing, support a targeted option, or identify a relevant clinical trial, repeat testing has a clear clinical purpose.
If the likely results would not materially change management, more molecular information may add biological detail without improving the immediate treatment decision.
A new molecular finding matters when biology and actionability meet
Once testing is pursued, the important question shifts from whether something new can be detected to whether that finding can be acted upon.
In the survey, 44.9% of oncologists identified finding an actionable resistance alteration as a leading purpose of repeat testing. The same proportion selected guiding subsequent treatment choice or sequencing.
The connection between those two aims matters.
The broader principles of precision medicine help explain how molecular findings can guide treatment selection while still requiring careful clinical interpretation.
A new alteration may explain why the previous therapy stopped working, but explanation alone does not necessarily improve care.
The result becomes clinically more meaningful when it creates a credible next step: an evidence-supported targeted treatment, a different treatment sequence, a suitable combination, or potential clinical-trial eligibility.
The practical distinction is straightforward: finding something new is not the same as finding something actionable.
Tissue and ctDNA answer the same question through different routes
Repeat assessment after progression may involve tissue testing, blood-based testing such as circulating tumor DNA (ctDNA), or complementary approaches depending on the disease and clinical setting.
ctDNA can identify some tumor-derived molecular changes through a blood sample and may be useful when emerging or acquired resistance is being investigated.
But the choice between blood and tissue is not simply about which is easier to obtain.
Assay sensitivity, tumor biology, disease burden, tissue accessibility, previous treatment, and the alteration being sought can all influence the appropriate approach. A negative blood-based result may not always exclude a clinically relevant molecular change.
For clinicians, the more useful question is therefore not “Can this be tested in blood?” but “Which approach is most likely to answer the current treatment question?”
Sometimes one method may be sufficient. In other settings, tissue and blood may provide complementary information.
A resistance finding does not automatically mean another targeted therapy
Even when testing identifies a plausible resistance mechanism, another targeted treatment is not automatically the next step.
The molecular result still needs to be considered alongside evidence strength, expected efficacy, toxicity, prior therapy, disease trajectory, patient factors, treatment availability, and clinical-trial options.
A matched therapy may offer the clearest next strategy for one patient. For another, an established treatment with a different mechanism may remain the stronger choice.
This is where the distinction between molecular information and molecular decision-making becomes important.
Molecular information can reshape the treatment hierarchy without replacing the broader oncology decision.
The real test of repeat molecular testing is whether treatment changes
The MDForLives survey provides a useful perspective on clinical utility.
More than half of surveyed oncologists (53.6%), said molecular information after progression changes treatment sometimes, in selected patients.
That conditional impact reflects the reality of precision oncology.
A test can be technically successful and biologically informative while still not producing a treatment option that is appropriate, supported, or accessible. Conversely, the right result in the right clinical context may substantially change sequencing or trial eligibility.
That makes decisions change a more useful measure of molecular testing than simply counting tests performed or alterations detected.
Once the result returns, the practical question is: does this information improve the next treatment decision compared with the alternatives already available?
Better testing cannot solve a treatment-availability problem by itself
The strongest barrier identified by surveyed oncologists appears after the molecular information is generated. Some 68.1% identified limited effective treatment options after progression as a major challenge in managing targeted therapy resistance.
That finding places an important limit on what better testing can achieve.
More sensitive assays and improved characterization of resistance can reduce uncertainty. But greater biological precision does not automatically create an effective therapy.
These challenges reflect a broader issue in precision oncology: translating molecular insights into effective, accessible treatment decisions.
The pathway therefore needs progress on both sides: better identification of resistance and better options for acting on what is found.
Clinical trials, multidisciplinary molecular interpretation, and access to emerging treatments become particularly relevant when a result is biologically meaningful, but established treatment options remain limited.
Closing perspective: test again when the answer can change the next step
After cancer progression, repeat molecular testing can help determine whether targeted therapy resistance reflects a clinically meaningful change in tumor biology.
But the strongest reason to retest is not simply that the tumor may have changed. It is that understanding that change could improve the next decision.
A practical pathway is to confirm progression, reassess the likely resistance biology, and determine whether new molecular information could be actionable. The next step is to select the appropriate testing approach and interpret the result within the full treatment context.
For oncology teams, molecular testing in cancer is most valuable when testing and treatment planning remain connected.
The precision of the molecular result matters. The precision of the decision matters even more.
Frequently Asked Questions
When should molecular testing be repeated after cancer progression?
Repeat molecular testing may be useful when a new result could influence treatment selection, sequencing, or clinical-trial eligibility. The decision depends on cancer type, previous therapy, suspected resistance mechanisms, available treatment options, tissue access, and applicable disease-specific guidance.
Can cancer mutations change after targeted therapy?
Tumor biology can evolve during treatment. Resistance may involve changes in the original target, activation of alternative pathways, or emergence of resistant tumor populations, making an earlier molecular profile less representative after progression.
Can ctDNA be used instead of another tissue biopsy?
ctDNA can identify some tumor-derived molecular alterations through blood and may be useful in selected settings. However, its sensitivity and clinical role vary by cancer type and assay, and a negative blood result does not always exclude a relevant alteration. Tissue testing may still be appropriate in some cases.
Does finding a new mutation always change cancer treatment?
No. A molecular finding needs to be clinically relevant and linked to an evidence-supported, appropriate, and available treatment strategy or clinical trial before it can meaningfully change management.
What happens if repeat molecular testing finds no actionable alteration?
Treatment decisions may then rely more heavily on disease trajectory, previous response, established treatment options, toxicity, patient factors, and clinical-trial availability. Further molecular or tissue assessment may be considered selectively when it could clarify an unresolved treatment question.
